IMMUNITYBIO, INC. (IBRX) Operating cash flow 2016–2025
IMMUNITYBIO, INC. (IBRX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$304.9MFY2025 · since FY2016: -$38.6M → -$304.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$304.9M | +22.1% |
| FY2024 | -$391.2M | -6.7% |
| FY2023 | -$366.8M | -8.7% |
| FY2022 | -$337.5M | -23.0% |
| FY2021 | -$274.4M | -59.8% |
| FY2020 | -$171.7M | -12.9% |
| FY2019 | -$152.1M | -140.0% |
| FY2018 | -$63.4M | -29.9% |
| FY2017 | -$48.8M | -26.4% |
| FY2016 | -$38.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More IBRX financial trends
IBRX RevenueIBRX Net incomeIBRX Net marginIBRX Gross profitIBRX Gross marginIBRX Operating incomeIBRX Operating marginIBRX Free cash flowIBRX Capital expendituresIBRX Return on equityIBRX Stock buybacksIBRX Dividends paidIBRX Total assetsIBRX Total liabilitiesIBRX Shareholders’ equityIBRX overview →